Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Muzastotug by Adagene Suzhou for Non-Small Cell Lung Cancer: Likelihood of Approval
Muzastotug is under clinical development by Adagene Suzhou and currently in Phase II for Non-Small Cell Lung Cancer. According to...
Muzastotug by Adagene Suzhou for Endometrial Cancer: Likelihood of Approval
Muzastotug is under clinical development by Adagene Suzhou and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase...
Muzastotug by Adagene Suzhou for Cervical Cancer: Likelihood of Approval
Muzastotug is under clinical development by Adagene Suzhou and currently in Phase II for Cervical Cancer. According to GlobalData, Phase...
Muzastotug by Adagene Suzhou for Uveal Melanoma: Likelihood of Approval
Muzastotug is under clinical development by Adagene Suzhou and currently in Phase II for Uveal Melanoma. According to GlobalData, Phase...
Muzastotug by Adagene Suzhou for Metastatic Ovarian Cancer: Likelihood of Approval
Muzastotug is under clinical development by Adagene Suzhou and currently in Phase II for Metastatic Ovarian Cancer. According to GlobalData,...
Muzastotug by Adagene Suzhou for Solid Tumor: Likelihood of Approval
Muzastotug is under clinical development by Adagene Suzhou and currently in Phase II for Solid Tumor. According to GlobalData, Phase...
Muzastotug by Adagene Suzhou for Hepatocellular Carcinoma: Likelihood of Approval
Muzastotug is under clinical development by Adagene Suzhou and currently in Phase II for Hepatocellular Carcinoma. According to GlobalData, Phase...
Muzastotug by Adagene Suzhou for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
Muzastotug is under clinical development by Adagene Suzhou and currently in Phase II for Head And Neck Squamous Cell Carcinoma...
Muzastotug by Adagene Suzhou for Metastatic Pancreatic Cancer: Likelihood of Approval
Muzastotug is under clinical development by Adagene Suzhou and currently in Phase II for Metastatic Pancreatic Cancer. According to GlobalData,...
Muzastotug by Adagene Suzhou for Metastatic Melanoma: Likelihood of Approval
Muzastotug is under clinical development by Adagene Suzhou and currently in Phase II for Metastatic Melanoma. According to GlobalData, Phase...
Muzastotug by Adagene Suzhou for Colorectal Cancer: Likelihood of Approval
Muzastotug is under clinical development by Adagene Suzhou and currently in Phase II for Colorectal Cancer. According to GlobalData, Phase...
Muzastotug by Adagene Suzhou for Renal Cell Carcinoma: Likelihood of Approval
Muzastotug is under clinical development by Adagene Suzhou and currently in Phase II for Renal Cell Carcinoma. According to GlobalData,...
Muzastotug by Adagene Suzhou for Metastatic Colorectal Cancer: Likelihood of Approval
Muzastotug is under clinical development by Adagene Suzhou and currently in Phase II for Metastatic Colorectal Cancer. According to GlobalData,...